0001493152-23-036581.txt : 20231006 0001493152-23-036581.hdr.sgml : 20231006 20231006184355 ACCESSION NUMBER: 0001493152-23-036581 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231004 FILED AS OF DATE: 20231006 DATE AS OF CHANGE: 20231006 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sakiris Spiro Kevin CENTRAL INDEX KEY: 0001830957 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39825 FILM NUMBER: 231315190 MAIL ADDRESS: STREET 1: 708 THIRD AVENUE, 6TH FLOOR CITY: NEW YORK CITY STATE: NY ZIP: 10017 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INTELLIGENT BIO SOLUTIONS INC. CENTRAL INDEX KEY: 0001725430 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 821512711 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 142 WEST 57TH ST FL11 CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 646-233-6971 MAIL ADDRESS: STREET 1: 142 WEST 57TH ST FL11 CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: GBS Inc. DATE OF NAME CHANGE: 20190919 FORMER COMPANY: FORMER CONFORMED NAME: Glucose Biosensor Systems (Greater China) Holdings, Inc. DATE OF NAME CHANGE: 20171214 4 1 ownership.xml X0508 4 2023-10-04 0 0001725430 INTELLIGENT BIO SOLUTIONS INC. INBS 0001830957 Sakiris Spiro Kevin C/O INTELLIGENT BIO SOLUTIONS INC., 142 WEST 57TH STREET, 11TH FLOOR NEW YORK NY 10019 0 1 0 0 Chief Financial Officer 0 Common Stock 3765 D Common Stock 2023-10-04 4 P 0 112727 A 117427 I Held by Anest Holdings Pty Ltd Common Stock Warrants (Series E) 2023-10-04 4 P 0 112727 A 2029-04-04 Common Stock 112727 112727 I Held by Anest Holdings Pty Ltd Common Stock Warrants (Series F) 2023-10-04 4 P 0 112727 A 2025-04-04 Common Stock 112727 112727 I Held by Anest Holdings Pty Ltd The reported securities are included within 112,727 INBS Class A Units purchased by the reporting person for $0.55 per Unit. Each Unit consists of one share of the common stock, one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series E Warrants"), and one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series F Warrants"). The Warrants will be exercisable beginning on the effective date of such stockholder approvals as may be required by the applicable rules and regulations of the Nasdaq Capital Market (or any successor entity) to permit the exercise of the Warrants ("Warrant Stockholder Approval"). The exercise price of the Series E Warrants is $0.55 per share. However, under the one-time reset provision of the Series E Warrants, the exercise price of the Series E Warrants will reset to a price equal to the lesser of (i) the then exercise price and (ii) 90% of the five-day volume weighted average price for the five trading days immediately following the date the Company effects a reverse stock split. The exercise price of the Series F Warrants is $0.55 per share. However,under the alternate cashless exercise option of the Series F Warrants, the holder of the Series F Warrant (beginning on the date the Warrant Stockholder Approval is effective), has the right to receive an aggregate number of shares of Common Stock on a one-for-one basis (subject to adjustment). These securities are held by Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, of which Mr. Sakiris is a director. /s/ Spiro Sakiris 2023-10-06